Gujarat Themis Biosyn reports robust Q2 FY26 performance with increased capacity

Gujarat Themis Biosyn Limited (GTBL) announced a strong performance for the second quarter and first half of fiscal year 2025-26. For Q2 FY26, the company reported a 22% year-on-year increase in revenue, reaching Rs. 42.3 crores. EBITDA grew by 36.3% to Rs. 20.9 crores, while Profit After Tax (PAT) rose by 35.3% to Rs. 14.3 crores. This growth was attributed to higher production and sales volumes, alongside cost optimization efforts.

A key milestone for GTBL was the completion of its new fermentation block expansion in October 2025, more than doubling its total capacity to 990 KL. Commercial production of Rifa-S and Rifa-O has already commenced in the new unit. The company’s API facility is also active, with validation batches in progress, aiming to integrate into fermentation-based and synthetic API offerings for export markets. GTBL's R&D expenditure for H1 FY26 was approximately 4% of its revenue, supporting the development of new molecules.

For the first half of FY26, total income from operations increased by 6.36% to Rs. 78.22 crores compared to H1 FY25. EBITDA saw a 2.80% rise to Rs. 34.86 crores, while PAT for H1 FY26 was Rs. 23.33 crores. The company also highlighted strategic investments in Capex over the last two years, leading to a higher Capital Employed & Asset base, while maintaining strong cash flows and low debt levels.